Research programme: dual incretin receptor agonists - Viking Therapeutics
Alternative Names: GLP-1/GIP dual agonist - Viking TherapeuticsLatest Information Update: 10 Nov 2021
At a glance
- Originator Viking Therapeutics
- Class Obesity therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity